1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Global Rheumatoid Arthritis Partnering 2010-2015

Global Rheumatoid Arthritis Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 250 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

Rheumatoid Arthritis Partnering 2010-2015 report provides understanding and access to the rheumatoid arthritis partnering deals and agreements entered into by the worlds leading healthcare companies.

•Trends in rheumatoid arthritis partnering deals
•Top rheumatoid arthritis deals by value
•Deals listed by company A-Z, industry sector, stage of development, technology type

Rheumatoid Arthritis Partnering 2010-2015 provides understanding and access to the rheumatoid arthritis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of rheumatoid arthritis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors rheumatoid arthritis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 200 links to online copies of actual rheumatoid arthritis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of rheumatoid arthritis partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in rheumatoid arthritis partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading rheumatoid arthritis deals since 2010. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of rheumatoid arthritis partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of rheumatoid arthritis technologies and products.

Report scope

Rheumatoid Arthritis Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to rheumatoid arthritis trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

•Trends in rheumatoid arthritis dealmaking in the biopharma industry since 2010
•Access to summary headline, upfront, milestone and royalty data
•The leading rheumatoid arthritis deals by value since 2010

In Rheumatoid arthritis Partnering 2010-2015, the available deals are listed by:

•Headline value
•Upfront payment value
•Royalty rate value
•Company A-Z
•Industry sector
•Stage of development at signing
•Deal component type
•Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Rheumatoid Arthritis Partnering 2010-2015 provides the reader with the following key benefits:


•In-depth understanding of rheumatoid arthritis deal trends since 2010
•Access to summary headline, upfront, milestone and royalty data
•Comprehensive access to over 200 actual rheumatoid arthritis deals entered into by the world’s biopharma companies since 2010
•Insight into key deal terms included in contracts, where disclosed
•Understand the key deal terms companies have agreed in deals
•Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Rheumatoid Arthritis Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in rheumatoid arthritis partnering

2.1. Introduction
2.2. Rheumatoid arthritis partnering over the years
2.3. Big pharma rheumatoid arthritis dealmaking activity
2.4. Big biotech rheumatoid arthritis dealmaking activity
2.5. Most active rheumatoid arthritis dealmakers
2.6. Rheumatoid arthritis partnering by deal type
2.7. Rheumatoid arthritis partnering industry sector
2.8. Rheumatoid arthritis partnering by stage of development
2.9. Rheumatoid arthritis partnering by technology type
2.10. Disclosed financial deal terms for rheumatoid arthritis
2.10.1 Rheumatoid arthritis headline values
2.10.2 Rheumatoid arthritis upfront payments
2.10.3 Rheumatoid arthritis milestone payments
2.10.4 Rheumatoid arthritis royalty rates

Chapter 3 - Leading rheumatoid arthritis deals

3.1. Introduction
3.2. Top rheumatoid arthritis deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Rheumatoid arthritis partnering since 2010
Figure 2: Big pharma - top 50 - rheumatoid arthritis deals 2010 to 2015
Figure 3: Big pharma rheumatoid arthritis deal frequency - 2010 to 2015
Figure 4: Big biotech - top 50 - rheumatoid arthritis deals 2010 to 2015
Figure 5: Big biotech rheumatoid arthritis deal frequency - 2010 to 2015
Figure 6: Rheumatoid arthritis dealmaking activity- 2010 to 2015
Figure 7: Rheumatoid arthritis partnering by deal type since 2010
Figure 8: Rheumatoid arthritis partnering by industry sector since 2010
Figure 9: Rheumatoid arthritis partnering by stage of development since 2010
Figure 10: Rheumatoid arthritis partnering by technology type since 2010
Figure 11: Rheumatoid arthritis deals with a headline value
Figure 12: Rheumatoid arthritis deals with upfront payment values
Figure 13: Rheumatoid arthritis deals with milestone payments
Figure 14: Rheumatoid arthritis deals with royalty rates, %
Figure 15: Top rheumatoid arthritis deals by value since 2010
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Rheumatoid Arthritis in 17 Major Markets Rheumatoid arthritis (RA) is classified as an autoimmune disease and occurs when the immune ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...

Osteoarthritis  - Market Insights, Epidemiology and Market Forecast-2023

Osteoarthritis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Osteoarthritis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.